FDA Investigator John D White
John D White has inspections in 11 countries as of 11 Oct 2023. John D White has collaborated with a combinined 3021 experts on various inspections, contributing to compliance and improvement across diverse sectors.
Investigator Details
Number of Inspected Sites:
25
Last Inspection Date:
11 Oct 2023
Investigator Role:
FDA Investigator
Redica ID:
Country:
United Kingdom of Great Britain and Northern Ireland,
China,
United States of America,
Italy,
Germany,
Japan,
Canada,
France,
Australia,
Ireland
Co-Investigator(s):
A Williams,
Alan P Kurtzberg,
Alberto A Viciedo,
Angela E Glenn,
Anh M Lac,
Anita Narula, PhD,
Ann L Demarco,
Anthony A Charity,
Arthur T Ogdahl,
Azza Talaat,
Barbara J Rincon,
Bijoy Panicker,
Bo Chi, PhD,
Bonita S Chester,
Brenda W Uratani, PhD,
Brooke K Higgins,
Candido Torres,
Carl A Huffman, III,
Carl Lee,
Carolyn E Barney,
CDR Rochelle B Young, RPh, MSA,
Charles M Edwards,
Charles R Cote, RIC,
Chiang Syin, PhD,
Christopher Downey, PhD,
Christopher S Keating,
Constantin Y Philopoulos,
Cynthia J Lee, MS,
Dawn E Barkans,
Denise M Digiulio,
Dennis Cantellops Paite,
Devaughn Edwards,
Diane L Raccasi,
Doan T Nguyen, PharmD,
Donald C Obenhuber, PhD,
Donald L Lech,
Dr. Chunchang Fang,
Dr. Ralph M Bernstein, PhD,
Dr. Robert C Horan, MD,
Dr. Willie F Vann, PhD,
Edecia A Richards,
Eliezar Ramos,
Elizabeth B Griffin,
Erika E Englund, PhD,
Erika V Butler,
Evaughn Edwards,
Felix Maldonado,
Garry H Stewart,
George Pyramides,
Ivis Lnegron Torres,
James C Maclaughlin,
James I Giefer,
James R Birkenstamm,
James W Leonette,
James W Plucinski,
Jeffrey A Sommers,
Jeffrey D Meng,
Jennifer J Stone,
Jennifer L Huntington,
Jonathan W Chapman,
Jorge L Gonzalez,
Jorge L Guadalupe,
Jose Alopez Rubet,
Jose R Hernandez,
Joyce A Kellett,
Julie D Bringger,
Justin A Boyd,
Kalavati Suvarna, PhD,
Kara D Dobbin,
Karyn M Campbell,
Katherine Szestypalow,
Kathleen R Jones, PhD,
Kevin A Gonzalez,
Kevin D Kallander,
Khoa Nathanv Tran,
Kristen D Evans,
Kurt A Brorson, PhD,
Larry K Austin,
Latorie S Jones,
LCDR Wilfred A Darang,
Loretta Nemchik,
Luella J Rossi,
Luis A Dasta,
Margaret M Annes,
Mariza M Jafary,
Mark Brunswick, PhD,
Mark E Parmon,
Mark P Prusak,
Mary E Storch,
Matthew B Casale,
Megan A Haggerty,
Michael A Charles,
Michael A Taylor,
Michael K Larson,
Michael L Chasey,
Michael R Goga,
Michael Shanks, MS,
Michelle D Haamid,
Michelle M Noe,
Michelle Y Clark Stuart,
Mihaly S Ligmond,
Milos Dokmanovic, PhD,
Monica Commerford, PhD,
Mra Munizn,
Nasir Ali, PhD,
Noreen Muniz,
Omotunde O Osunsanmi,
Patrick C Klotzbuecher,
Paul M Kawamoto,
Peter E Baker,
Philip F Istafanos, DMV, MS,
Prabhu P Raju,
Qing Joanna Zhou, PhD,
Reba A Gates,
Regina T Brown,
Reyes Candau Chacon, PhD,
Richard E Needham,
Richard J Friedman,
Richard L Rutherford,
Richard Ledwidge (nmi), PhD,
Richard W Berning,
Robert C Horu, PhD,
Robert D Tollefsen,
Robert J Martin,
Robert W Jennings,
Rochelle K Kimmel,
Roger F Zabinski,
Rose M Ashley,
Sarah E Mcmullen,
Scott T Ballard,
Sharon K Thoma, PharmD,
Simone E Pitts,
Stephen J Koniers,
Steven M Weinman,
Susan F Laska, MS,
Susan W Ting,
Syed N Ali,
Tamara Brey,
Tania K Mercado,
Temar Q Williams,
Teresa C Thompson,
Teresa I Navas,
Teresa Jimenez,
Terri L Dodds,
Thomas E Friel,
Thomas H Jenkins,
Thomas J Arista,
Thuy T Nguyen, LCDR,
Torrance J Slayton,
Veronica Fuentes, MS,
Victor Spanioli,
Virgilio F Pacio, CSO,
Walter N Lange,
Wayne D Mcgrath,
Wayne E Seifert,
Yanming An, PhD,
Yasamin Ameri,
Yvette I Johnson,
Zedong Dong,
Zerita White,
Zhihao Qiu (Peter), PhD,
Zhong Li, PhD,
Ziyang Su, PhD
John D White's Documents
| Publish Date | Document Type | Title |
|---|---|---|
| September, 2002 | EIR | Boehringer Ingelheim Pharma GmbH and Co. KG - EIR, 2002-09-16 |
| September, 2002 | FDA 483 Response | Boehringer Ingelheim Pharma GmbH and Co. KG - Form 483R, 2002-09-18 |
| September, 2002 | FDA 483 Response | Boehringer Ingelheim Pharma GmbH and Co. KG - Form 483R, 2002-09-16 |
| April, 2003 | EIR | Kyowa Hakko Kirin Co., Ltd. - EIR, 2003-04-03 |
| April, 2003 | FDA 483 | KAKEN Pharmaceutical Co., LTD - Form 483, 2003-04-10 |
| September, 2002 | EIR | Boehringer Ingelheim Pharma GmbH and Co. KG - EIR, 2002-09-18 |
| April, 2003 | FDA 483 Response | Kyowa Hakko Kirin Co., Ltd. - Form 483R, 2003-06-20 |
| September, 2003 | FDA 483 | PRIMED INSTRUMENTS INC - Form 483, 2003-09-17 |
| May, 2001 | FDA 483 | Jiangsu Hengrui Medicine Co., Ltd. - Form 483, 2001-05-25 |
Experience Redica System's NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more